Results(4699)
TARGET-EU: Nivolumab plus ipilimumab with chemotherapy versus pembrolizumab with chemotherapy in patients with non-oncogenic metastatic non-small-cell lung cancer with <1% PD- L1 tumour expression
Netherlands
EU PAS number:
EUPAS1000000987
First published:
10/07/2026
Study
Planned
A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection (208165)
Netherlands
United Kingdom
EU PAS number:
EUPAS37605
First published:
10/07/2026
Study
Ongoing
An Observational Study to Determine the Incidence of Injection Reactions Among Patients With Multiple Sclerosis Treated With Ocrelizumab Subcutaneous
Argentina
Czechia
United Kingdom
United States
EU PAS number:
EUPAS1000001057
First published:
10/07/2026
Study
Planned
A Prospective Post-Marketing Observational Safety Study of Cyramza® (Ramucirumab) in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma in China (I4T-MC-B012)
China
EU PAS number:
EUPAS47676
First published:
10/07/2026
Study
Planned
A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
United States
EU PAS number:
EUPAS1000000327
First published:
10/07/2026
Study
Planned
REpositioning of Medications IN Dementia (REMIND)
France
EU PAS number:
EUPAS1000000484
First published:
10/07/2026
Study
Ongoing
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol
Spain
First published:
09/07/2026
Institution
Educational Institution
Laboratory/Research/Testing facility
Not-for-profit
ENCePP partner
Association between opioid use and the development of diverticulitis (Opioids Diverticulitis)
Canada
United Kingdom
United States
EU PAS number:
EUPAS104164
First published:
09/07/2026
Study
Finalised
PASS TachoSil Evaluation (PasTel): Short- and long-term safety evaluation of TachoSil in paediatric population
Poland
EU PAS number:
EUPAS1000000505
First published:
09/07/2026
Study
Planned
Estudio de utilización de medicamentos para el tratamiento de la insuficiencia cardíaca (IDIAP-IC-2025) / Drug utilization study of treatments for heart failure (IDIAP-IC-2025)
Spain
EU PAS number:
EUPAS1000000866
First published:
09/07/2026
Study
Ongoing
Utilization patterns of oral therapies in prostate cancer in Tuscany: a retrospective observational study based on regional administrative databases
Italy
EU PAS number:
EUPAS1000001049
First published:
09/07/2026
Study
Ongoing
Pharmacovigilance and Pharmacoepidemiology Research Unit, Department Neurofarba, University of Florence
Italy
First published:
08/07/2026
Institution
Educational Institution
ENCePP partner
National Diabetes Research Platform Scotland
Other
United Kingdom
First published:
08/07/2026
Data source
Human
Record completeness: 97%
MEASuRE: Metreleptin Effectiveness and Safety Registry
France
Germany
Italy
United Kingdom
United States
EU PAS number:
EUPAS1000001052
First published:
08/07/2026
Study
Ongoing
Background Incidence Rates of Selected Vaccine Adverse Events of Special Interest in Canada
Canada
EU PAS number:
EUPAS1000001053
First published:
08/07/2026
Study
Ongoing
The Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update
Canada
EU PAS number:
EUPAS107333
First published:
08/07/2026
Study
Finalised
Post-Marketing Study to Assess the Effectiveness and Safety of RECARBRIO in Chinese Adult Patients With Limited or No Alternative Treatment Options for Susceptible Gram-Negative Bacterial Infections (MK-7655A-035)
China
EU PAS number:
EUPAS1000001027
First published:
08/07/2026
Study
Planned
Nederlandse Cystic Fibrosis Stichting (NCFS)
Netherlands
First published:
07/07/2026
Institution
Patient organisation/association
Unit of adverse drug reactions monitoring (UADRM), University Hospital of Pisa
Italy
First published:
07/07/2026
Institution
Educational Institution
Hospital/Clinic/Other health care facility
ENCePP partner
Belgian Cancer Registry (breast and lung cancer)
Cancer registry
Belgium
First published:
07/07/2026
Data source
Human
Record completeness: 69%
DARWIN EU® - Assessing the feasibility of conducting a causal study on the potential association between beta-blockers and breast cancer
Denmark
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000001013
First published:
07/07/2026
Study
Ongoing
209696 - A targeted safety study, EPI-ZOSTER-032 VS US DB, to evaluate the safety of Shingrix in adults ≥ 65 years of age in the United States.
United States
EU PAS number:
EUPAS37133
First published:
07/07/2026
Study
Finalised
DARWIN EU® - Multiple myeloma: patient characterisation, treatments, and survival in the period 2012–2024
Denmark
Finland
France
Germany
Norway
Spain
Sweden
EU PAS number:
EUPAS1000000757
First published:
07/07/2026
Study
Finalised
LOWER: Lomitapide Observational Worldwide Evaluation Registry (AEGR-733-025)
Canada
France
Greece
Italy
Netherlands
United Kingdom
United States
EU PAS number:
EUPAS5326
First published:
07/07/2026
Study
Ongoing
PATTERN OF USE AND SAFETY PROFILE OF BRANDED VS GENERIC ANTIEPILEPTIC DRUGS
Italy
EU PAS number:
EUPAS24224
First published:
07/07/2026
Study
Finalised
Comparative Effectiveness and Safety of Drugs used in Rare Neuromuscular and Neurodegenerative Diseases (CAESAR)
Italy
EU PAS number:
EUPAS37983
First published:
07/07/2026
Study
Planned
Maternal Outcomes following RSVpreF Vaccination during prEgnancy (MORE)
United States
EU PAS number:
EUPAS1000000923
First published:
07/07/2026
Study
Ongoing
Department of Statistics, Informatics and Applications 'Giuseppe Parenti', University of Florence.
Italy
First published:
06/07/2026
Institution
Educational Institution
Centro Regionale di Farmacovigilanza della Toscana (CRFVT)
Italy
First published:
06/07/2026
Network
ENCePP partner
ADEPT: The utilisation of antiseizure medications in pregnant women, and women and men of childbearing age: a multi-database study from 6 European countries
Finland
France
Italy
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000212
First published:
06/07/2026
Study
Ongoing
Evolution of Prescribing Patterns of Antidiabetic and Anti-Obesity Drugs in the Tuscany Region: An Integrated of Utilization and Safety Analysis, and the Role of AIFA Note 100 (PATTERN-100 Prescribing PATTERNs of Antidiabetic and Anti-obesity Drugs: Utilization, Safety and the Role of AIFA Note 100)
Italy
EU PAS number:
EUPAS1000001050
First published:
06/07/2026
Study
Finalised
Frequency of HIV diagnoses among people using oral and LA PrEP (223555)
United States
EU PAS number:
EUPAS1000000371
First published:
06/07/2026
Study
Ongoing
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir: Data from The Antiretroviral Pregnancy Registry (APR) (215325)
Australia
Botswana
Canada
Czechia
Eswatini
France
Germany
Italy
Kenya
Malawi
Netherlands
Portugal
Russian Federation
South Africa
Spain
Uganda
United Kingdom
United States
Zimbabwe
EU PAS number:
EUPAS45685
First published:
06/07/2026
Study
Ongoing
An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients with Non-dystrophic Myotonic Disorders
France
Germany
United Kingdom
EU PAS number:
EUPAS37943
First published:
06/07/2026
Study
Ongoing
Postauthorization Safety Study Survey to Evaluate the Effectiveness of the Ciltacabtagene Autoleucel HCP Educational Program and the Product Handling Training
Austria
Belgium
Denmark
Germany
Portugal
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS1000000047
First published:
06/07/2026
Study
Ongoing
A Drug Utilisation Study of Qsiva for Weight Management: A Postmarketing Cohort Database Study in Denmark, Finland, Norway, and Sweden
Denmark
Finland
Norway
Sweden
EU PAS number:
EUPAS1000000883
First published:
06/07/2026
Study
Ongoing
The Eplontersen Pregnancy and Lactation Outcomes Study: A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen (EPPRO)
Argentina
Armenia
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
China
Croatia
Czechia
Denmark
Estonia
European Union
Finland
France
Georgia
Germany
Greece
Greenland
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Korea, Democratic People's Republic of
Latvia
Lithuania
Luxembourg
Netherlands
New Zealand
Norway
Other
Poland
Portugal
Romania
Singapore
South Africa
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Arab Emirates
United Kingdom
United Kingdom (Northern Ireland)
United States
EU PAS number:
EUPAS1000000736
First published:
03/07/2026
Study
Ongoing
Long-term cardiovascular safety and real-world use of eptinezumab - An observational, historical cohort study of patients initiating eptinezumab in routine clinical practice
Denmark
Germany
Italy
United States
EU PAS number:
EUPAS1000000882
First published:
03/07/2026
Study
Planned
A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)
Denmark
Spain
EU PAS number:
EUPAS1000000480
First published:
02/07/2026
Study
Ongoing
Effectiveness of ROTATEQ® when administered with intervals greater than 10 weeks between doses in Chinese children: an observational study of V260-077 study participants with longer dosing interval (V260-080)
China
EU PAS number:
EUPAS1000000730
First published:
02/07/2026
Study
Finalised
Compare data sources
Compare data sources